OnCo
trialsTrialPlanned

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

A phase 2 trial of the registered interventions in gallbladder cancer and other biliary tract cancers, run by GV20 Therapeutics, not yet recruiting.